Abstract
Background: Cardiovascular diseases are amongst the prime reasons of increasing morbidity as well as mortality worldwide. Dyslipidemia is an important and modifiable risk factor of CVD and statins are extremely endorsed in its treatment. Method: Data was acquired from the online edition of “Current Index of Medical Specialties” (CIMS), 1mg, netmeds. The percentage cost variation as well as cost ratio were calculated. Result: Percentage cost variation was recorded highest in atorvastatin 10mg (3668.50%) whereas, the least percentage cost variation was recorded for pravastatin 10mg (3.61%). Conclusion: To reduce the burden on patients, the government should cover as many as possible drugs under the drug price control order (DPCO) and develop uniformity in the pricing of the drugs. Keywords: Hypolipidemic drugs, cardiovascular diseases, cost variation, statins, brands
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
